About this trial
The goal of this phase 1 study is to investigate the safety and efficacy of dimethyltryptamine (DMT) in individuals with depression and healthy controls. We hypothesize that administration of DMT will result in decreases in depression, associated symptoms, and neuroplastic changes in depressed subjects. We expect that DMT will induce changes in neuroplasticity as indexed using electroencephalographic (EEG) measures and tasks in both depressed individuals and healthy volunteers, though to different degrees. These neuronal changes may in parallel cause changes in mood measured both in healthy and depressed subjects, which will be captured using appropriate psychometric measures of mood.
Eligibility criteria
Qualifiers
Males and females
Age 21 to 65 years
Body mass index between 18-35 kg/m2
Willing to refrain from taking any medications not approved by the study physician
Disqualifiers
Medications that might significantly interfere with the effects of the study medications
Cognitive dysfunction that could interfere with study participation
Alcohol or substance use disorder
Any lifetime history of hallucinogen use disorder
Trial design
Treatments tested in this trial
- DMT-Medium Dose
- DMT-Low Dose
- THC-Medium Dose
- THC-Low Dose
Treatment groups
Sponsors and collaborators
Deepak C. D'Souza
Lead sponsor
Yale University
Sponsor institution